A locally developed nutraceutical targeting cancer stem cells is projected to generate around two million U.S. dollars in export revenue for Sri Lanka by 2027, according to Prof. Sameera R. Samarakoon of the Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo.
Launched three years ago, the product has already gained popularity among Sri Lankan consumers, receiving positive feedback for its effectiveness in improving quality of life.
While clarifying that it is not a drug, Prof. Samarakoon explained that the nutraceutical was designed as an alternative approach in the fight against cancer. “Various methods exist to combat cancer, including surgery, chemotherapy, radiotherapy, targeted therapies, vaccines, and traditional treatments. Our focus was to develop a product to fight cancer stem cells and support patients in living better lives,” he said.
He added that the formula may not only offer direct anticancer activity but could also help reduce side effects commonly associated with cancer treatments. “It may alleviate therapy-induced toxicity, making it a potential adjunct to traditional cancer therapies,” he noted.
A survey conducted last year by the University of Kelaniya with over 300 participants reported a 93 percent satisfaction rate for the product.
Prof. Samarakoon said further preclinical and clinical studies are underway in collaboration with institutions such as the University of Ruhuna and the Faculty of Indigenous Medicine, University of Colombo. Plans are also being made to partner with international research centers to validate the product’s effectiveness and expand its global recognition.
He emphasized that the long-term goal is to establish the nutraceutical as an internationally recognized cancer-fighting product while contributing significantly to Sri Lanka’s economy through exports.
